Substance / Medication

Estramustine phosphate sodium

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Neoplasm of prostate

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:

Diagnostic accuracy of multiparametric MRI for detecting unconventional prostate cancer histology: a systematic review and meta-analysis.

Carletti Filippo, Maggi Martina, Fazekas Tamas et al. · Eur Radiol · 2026

PMID: 40307530Meta-AnalysisFull text (PMC)

The efficacy and safety of enzalutamide in metastatic hormone-sensitive prostate cancer: a meta-analysis based on subgroups and reconstructed individual patient data.

Zhang Fuxun, Luo Zhirong, Xue Qi et al. · Int Urol Nephrol · 2026

PMID: 40660075Meta-Analysis

Chinese medicines as therapeutic options for treating prostate cancer: Therapeutic effects and underlying mechanisms.

Li Shenglong, Jing Shuaishuai, Zhou Jiuyun et al. · J Ethnopharmacol · 2026

PMID: 40882785Meta-Analysis

Necessity of re-evaluation of estramustine phosphate sodium (EMP) as a treatment option for first-line monotherapy in advanced prostate cancer.

Kitamura T · Int J Urol · 2001

PMID: 11240822Review

Estramustine phosphate sodium in heavily pretreated patients with metastatic breast cancer: a retrospective consecutive case series.

Aurilio Gaetano, Graffeo Rossella, Bagnardi Vincenzo et al. · Int J Clin Oncol · 2015

PMID: 24722887Other

Efficacy of tegafur-uracil (UFT) administration in castration-resistant prostate cancer patients with a history of both alternative antiandrogen therapy and estramustine phosphate sodium hydrate therapy.

Hayakawa Nozomi, Matsumoto Kazuhiro, Sato Atsuko et al. · Int Urol Nephrol · 2014

PMID: 24356920Other

Efficacy of estramustine phosphate sodium hydrate (EMP) monotherapy in castration-resistant prostate cancer patients: report of 102 cases and review of literature.

Matsumoto Kazuhiro, Tanaka Nobuyuki, Hayakawa Nozomi et al. · Med Oncol · 2013

PMID: 24005812Other

Single-nucleotide polymorphisms in the 17beta-hydroxysteroid dehydrogenase genes might predict the risk of side-effects of estramustine phosphate sodium in prostate cancer patients.

Suzuki Motofumi, Muto Satoru, Hara Kazuo et al. · Int J Urol · 2005

PMID: 15733111Other

[A clinical study of estramustine phosphate sodium for the treatment of hot flushes in men with prostate cancer].

Fukuhara Shinichiro, Yokoyama Shohei, Tsutahara Koichi et al. · Nihon Hinyokika Gakkai Zasshi · 2004

PMID: 15508700Other

[Effect of the 5-HT3 receptor antagonist granisetron on estramustine phosphate sodium (Estracyt)-induced emesis in ferrets].

Higashioka Masaya, Yamaguchi Emi, Takatori Shingo et al. · Hinyokika Kiyo · 2010

PMID: 20724808Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Estramustine phosphate sodium (substance)
SNOMED CT: 108769008
UMLS CUI: C0014922

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.